Clinical trials: 2019-nCoV Pneumonia
2019-nCoV
A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia
At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of two therapeutic schemes(abidol…
- Trial name
- NCT04254874
- Testing
- Abidol hydrochloride, Abidol Hydrochloride combined with Interferon atomization
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital
Multiple Sclerosis, COVID-19 (Severe Coronavirus Disease 2019)
A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.
This nested project of the Swiss Multiple Sclerosis Cohort (SMSC) is to assess the severity of COVID-19 and the magnitude of antibody response after infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in…
- Trial name
- MS COVID-19 (NCT04760990)
- Testing
- data collection, analysis of blood samples
- Where
- 7 sites in Switzerland
- Volunteers
- 1,181 people
- Sponsor
- University Hospital, Basel, Switzerland
COVID-19
Interest in the Use of Nasal High-Flow Oxygen Therapy (OptiFlow™) in Secondary Transport of COVID-19 Positive Patients
Since the beginning of COVID-19 pandemic situation, several modes of ventilation have been tried to correct the hypoxaemia induced by SARS-CoV-2 virus.
- Trial name
- SAMU83 (NCT05289141)
- Testing
- Use of high flow nasal oxygen therapy, Use of other non-invasive ventilation or high concentration oxygen masks
- Where
- France
- Volunteers
- 229 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
COVID
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).
- Trial name
- NCT04447469
- Testing
- mavrilimumab
- Where
- 32 sites in United States, Brazil and 3 more
- Volunteers
- 814 people
- Sponsor
- Kiniksa Pharmaceuticals International, plc
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
SARS-CoV-2
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19.
- Trial name
- NCT07266558
- Testing
- mRNA-1273, mRNA-1283
- Where
- 150 sites in United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID - 19
Safety and Immunogenicity of a Chimeric Recombinant Covid19 Vaccine SpiN-Tec MCTI UFMG
SpiN-Tec MCTI UFMG will be used as a vaccine booster against COVID-19 and will be evaluated using the active comparator, a vaccine approved by ANVISA (Brazilian Health Regulatory Agency).
- Trial name
- SpiN-Tec-001 (NCT07134725)
- Testing
- SpiN-Tec MCTI UFMG, Active Comparator: Covishield® vaccine, Active Comparator: Comirnaty® vaccine
- Where
- Brazil
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Hypertension, COVID-19
Coronavirus (COVID-19) ACEi/ARB Investigation
Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- CORONACION (NCT04330300)
- Testing
- Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor
- Where
- Ireland
- Volunteers
- 2,414 people
- Sponsor
- National University of Ireland, Galway, Ireland
COVID-19
Losmapimod Safety and Efficacy in COVID-19
The therapeutic hypothesis for the use of losmapimod in COVID-19 disease is that increased mortality and severe disease is caused by p38 mitogen-activated protein kinase (MAPK)-mediated exaggerated acute inflammatory response…
- Trial name
- LOSVID (NCT04511819)
- Testing
- Losmapimod oral tablet
- Where
- 16 sites in United States, Brazil and 2 more
- Volunteers
- 52 people
- Sponsor
- Fulcrum Therapeutics
ARDS, COVID-19
Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)
To evaluate the safety, toxicity and immunological effects of infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells (MSCs) and whether this therapy has an influence on the resolution processes in ARDS…
- Trial name
- NCT04377334
- Testing
- MSC
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University Hospital Tuebingen
COVID-19
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
This study is designed to evaluate three dose levels of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) (COVID-HIGIV) for safety and pharmacokinetics (PK) in healthy adults.
- Trial name
- NCT04661839
- Testing
- COVID-HIGIV
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Critically Illness, Sedation
Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)
The authors hypothesized that inhaled sedation, either with isoflurane or sevoflurane, might be associated with improved clinical outcomes in patients with COVID-19-related ARDS, compared to intravenous sedation.
- Conditions
- Critically Illness, Sedation, Invasive Mechanical Ventilation, Acute Respiratory Distress Syndrome
- Trial name
- ISCA (NCT04383730)
- Testing
- Intravenous sedation, Inhaled sedation
- Where
- 12 sites in United States, France and 3 more
- Volunteers
- 203 people
- Sponsor
- University Hospital, Clermont-Ferrand
Infections, Respiratory, Virus Diseases
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was cancelled due to changes in the overall clinical development plan.
- Conditions
- Infections, Respiratory, Virus Diseases, Infection Viral, Vaccine Adverse Reaction
- Trial name
- NCT04380701
- Testing
- BNT162a1, BNT162b1, BNT162b2
- Where
- 5 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Acute Disease, Coronavirus
Evaluation of Novel Diagnostic Tests for COVID-19
COVID-19 (also known as Coronavirus) originated in the Wuhan China and has since spread to at least 159 countries around the world. It was declared a pandemic by the World health organisation on the 11th of March 2020.
- Conditions
- Acute Disease, Coronavirus, Respiratory Viral Infection
- Trial name
- COVIDx (NCT04326387)
- Testing
- SAMBA II (Diagnostic for the Real World), Public Health England Gold Standard, Cambridge Validated Viral Detection Method
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- CCTU- Cancer Theme
CoronaVirus Disease-2019 (COVID-19)
Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- NCT04644120
- Testing
- ABBV-47D11, ABBV-2B04
- Where
- 18 sites in United States, Hungary and 3 more
- Volunteers
- 25 people
- Sponsor
- AbbVie
Covid19, Coronavirus Infection
Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients
This retrospective analysis of inpatient data obtained from administrative and electronic medical records will investigate the role of empiric antibiotics on admission on the mortality for non-intubated patients presenting with…
- Conditions
- Covid19, Coronavirus Infection, Pneumonia
- Trial name
- NCT04674410
- Testing
- Antibiotic
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Virus; Pneumonia
A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia
Due to the outbreak of 2019 Novel Coronavirus Pneumonia in Wuhan, Hubei province, medical staff and residents are facing great psychological pressure, the investigator plan to use electronic questionnaire to carry out…
- Trial name
- NCT04260308
- Where
- China
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- Huazhong University of Science and Technology
COVID-19 SARS-CoV-2 Infection, COVID-19
A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19
The purpose of this study is to learn about how well the yearly updates to the COVID-19 vaccine work in adults (age 18 years and above) with a healthy immune system (the body's cells, tissues and organs that work together to…
- Conditions
- COVID-19 SARS-CoV-2 Infection, COVID-19, COVID-19 Infection, Coronavirus Disease 2019 (COVID-19)
- Trial name
- NCT06923137
- Testing
- BNT162b2
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Evaluation of a Non-face to Face Multidisciplinary Health Care Model in a Population With Rheumatoid Arthritis
This research work proposes the evaluation of the implementation of a tele-orientation program and tele-consultation to the adult population with RA attended at a specialized rheumatology center in Bogota, Colombia, over a period…
- Trial name
- NCT04768413
- Testing
- Teleconsultation either by phone or by computer consultation. Quantitative and qualitative approaches to analysis, Care modalities. Quantitative and qualitative approaches to analysis
- Where
- 2 sites in Colombia
- Volunteers
- 200 people
- Sponsor
- Fundación Universitaria de Ciencias de la Salud
SARS Coronavirus (SARS-CoV-2) Infection
A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19
This study is to gain critical knowledge to understand the factors influencing the outcome of a pandemic virus within the city of Basel.
- Trial name
- NCT04351503
- Testing
- Study A, Study B, Study C
- Where
- 6 sites in Switzerland
- Volunteers
- 126,586 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland